Oral antiviral therapy to hepatitis B virus (HBV) with nucleos (t) ide analogues (NUCs) is
effective in suppressing the viral load leading to improved clinical outcomes. However …

Background & Aims Flares after nucleos (t) ide analogue (NA) cessation are common and
potentially harmful. Predictors of flares are required for risk stratification and to guide off …

Over 300 million individuals worldwide are chronically infected with hepatitis B virus and at
risk for progressive liver disease. Due to the lack of a therapy that reliably achieves viral …

Hepatitis B surface antigen (HBsAg) seroclearance, an indicator of recovery from hepatitis B
virus (HBV) infection, is uncommon in long-term nucleos (t) ide analog (NUC) therapy. We …

Background and aims The aim of this systematic literature review (SLR) was to examine
outcomes and associated predictors following nucleos (t) ide analogue (NA) treatment …

ABSTRACT Background Severe flares (ALT≥ 10× ULN) are a well‐recognised adverse
outcome after nucleos (t) ide analogue (NA) cessation and may lead to liver failure. Thus …

Increasing functional cure rates after nucleo(s)tide analogue withdrawal: is peg-IFN the
answer? Increasing functional cure rates after nucleo(s)tide analogue withdrawal: is peg-IFN …

Background Quantitative hepatitis B surface antigen (qHBsAg) level at end‐of‐treatment
(EOT) predict clinical relapse (CR) after nucleos (t) ide analogues (Nuc) in chronic hepatitis …

Nucleos (t) ide analogues (NUCs) are the standard and mostly lifelong treatment for chronic
HBeAg-negative hepatitis B, as functional cure (loss of HBsAg) is rarely achieved …

Editorial: Mitigating the risk of severe hepatitis flare following nucleoside analogue
discontinuation—Insights from a real‐ Page 1 548 | wileyonlinelibrary.com/journal/apt Aliment …